BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1760 related articles for article (PubMed ID: 33462141)

  • 1. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery.
    Shadbad MA; Asadzadeh Z; Derakhshani A; Hosseinkhani N; Mokhtarzadeh A; Baghbanzadeh A; Hajiasgharzadeh K; Brunetti O; Argentiero A; Racanelli V; Silvestris N; Baradaran B
    Biomed Pharmacother; 2021 Nov; 143():112213. PubMed ID: 34560556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
    Roshani Asl E; Rasmi Y; Baradaran B
    J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA
    Xu YJ; Zhao JM; Ni XF; Wang W; Hu WW; Wu CP
    Epigenomics; 2021 Aug; 13(16):1281-1297. PubMed ID: 34523356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model.
    Li J; Xu J; Yan X; Jin K; Li W; Zhang R
    Med Sci Monit; 2018 Aug; 24():5501-5508. PubMed ID: 30087314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer.
    Li S; Na R; Li X; Zhang Y; Zheng T
    Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188758. PubMed ID: 35809762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
    Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented Antitumor Effect of Unripe
    Lee EJ; Yang JH; Choi JG; Chung HS
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer.
    Chen YL; Wang GX; Lin BA; Huang JS
    Cell Biol Int; 2020 May; 44(5):1224-1236. PubMed ID: 32068322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy.
    Yi B; Cheng H; Wyczechowska D; Yu Q; Li L; Ochoa AC; Riker AI; Xi Y
    Mol Cancer Ther; 2021 Jul; 20(7):1295-1304. PubMed ID: 33879557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
    Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition.
    Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
    Wang C; Li X; Zhang L; Chen Y; Dong R; Zhang J; Zhao J; Guo X; Yang G; Li Y; Gu C; Xi Q; Zhang R
    Int Immunopharmacol; 2021 Aug; 97():107822. PubMed ID: 34098485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction.
    Shiri AM; Zhang T; Bedke T; Zazara DE; Zhao L; Lücke J; Sabihi M; Fazio A; Zhang S; Tauriello DVF; Batlle E; Steglich B; Kempski J; Agalioti T; Nawrocki M; Xu Y; Riecken K; Liebold I; Brockmann L; Konczalla L; Bosurgi L; Mercanoglu B; Seeger P; Küsters N; Lykoudis PM; Heumann A; Arck PC; Fehse B; Busch P; Grotelüschen R; Mann O; Izbicki JR; Hackert T; Flavell RA; Gagliani N; Giannou AD; Huber S
    J Hepatol; 2024 Apr; 80(4):634-644. PubMed ID: 38160941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer.
    Huntington KE; Louie AD; Srinivasan PR; Schorl C; Lu S; Silverberg D; Newhouse D; Wu Z; Zhou L; Borden BA; Giles FJ; Dooner M; Carneiro BA; El-Deiry WS
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
    Wang T; Wu L; Wang S; Shi X; Liu H; Deng W
    Chin J Nat Med; 2023 May; 21(5):333-345. PubMed ID: 37245872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
    Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.